Breast cancer male

6 trials 3 recruiting MedDRA PT
6 Registered trials
3 Recruiting
4 Unique sponsors
8 Unique IMPs
4 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 4
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Platinum compound 2 substances
Checkpoint inhibitor (PD-1) 1 substance
Antibody-drug conjugate (ADC) 1 substance
SERD 1 substance
CDK inhibitor 1 substance
Unknown / small molecule 1 substance
Antimetabolite 1 substance
Phase III: 3 Phase II: 2 Phase I (First in Human): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

3 trials
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    PEMBROLIZUMAB; SACITUZUMAB GOVITECAN
    2024-516734-35-00 1 country n=690
    Pending
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    ELACESTRANT; RIBOCICLIB
    2025-522484-15-00 3 countries 2026 n=1,520
    Recruiting
  • GBG Forschungs GmbH Academic
    CAPECITABINE; CARBOPLATIN; CISPLATIN; SACITUZUMAB GOVITECAN
    2023-510390-33-00 6 countries 2020 n=1,386
    Ended

Phase II

2 trials
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    PEMBROLIZUMAB; SACITUZUMAB GOVITECAN
    2023-508787-29-00 1 country 2024 n=348
    Recruiting
  • Institut fuer Frauengesundheit GmbH Academic
    IMP not specified
    2024-519350-37-00 1 country n=89
    Ended

Phase I (First in Human)

1 trial
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
WSG Westdeutsche Studiengruppe GmbH Commercial 3 Phase II, Phase III 2
Daiichi Sankyo Inc. Commercial 1 Phase I (First in Human) 1
Institut fuer Frauengesundheit GmbH Academic 1 Phase II 0
GBG Forschungs GmbH Academic 1 Phase III 0
New trials by year
2020
1
2024
1
2025
1
2026
1
← All indication landscapes